The global generic oncology drugs market value was USD 25.3 billion in 2023, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 6.2% during the forecast period of 2024-2032 to achieve a value of USD 43.7 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The global generic oncology drugs market is being driven by the growing cancer incidences across the globe coupled with rising demand for such drugs to assist patients undergoing chemotherapy, alleviating after-effects, including pain.
Region-wise, North America is the leading market for generic oncology drugs accounting for the majority of the global share. The growth of the market in the region can be attributed to the availability of advanced technology and enhanced healthcare infrastructure. On the other hand, the Asia Pacific is expected to be one of the emerging markets owing to the increased government expenditure in the healthcare sector in the region coupled with the presence of increased population.
Generic oncology drugs refer to the drugs that assist in shrinking, controlling, and eliminating the cancer cells present in the human body. They perform a pivotal role in cancer treatment as some of the anti-cancer drugs are only available in the form of generics. Generic oncology drugs share similar active ingredients as the already marketed brand-name cancer care medicine, and they can be characterised by different colours or flavours in comparison to the original drugs. The performance, intended use, quality, dosage form, and route of administration of these drugs are similar to that of their original counterparts.
The EMR report has analysed the major regional markets in the industry, which are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The generic oncology drugs market is driven by the growing prevalence of cancer across the globe, coupled with high costs associated with cancer treatment. These drugs are bioequivalent of and are used as an alternative means to brand-name medicines, providing similar pharmacological effects in cancer treatment. A rapid increase in the number of smokers, coupled with a rise in sedentary and unhealthy lifestyles, has increased the incidences of cancer cases around the world. As a result of this, there has been an acceleration in the demand for cost-effective and viable cancer treatments, including generic oncology drugs. Increasing adulteration in food products and the usage of pesticides in fresh fruits and vegetables has injected a lot of chemicals in the human body responsible for such diseases.
Apart from this, rising government expenditure in the emerging nations to promote generic drugs and reduce healthcare expenses is positively influencing the regional market growth. Furthermore, rapid advancements in the healthcare sector and biotechnology and research field have resulted in early and affordable cancer diagnosis, thus increasing the demand for generic oncology drugs at the prevention stage. Thus, rising geriatric population and growing demand for cost-effective treatment procedures, particularly in emerging regions are aiding the industry further.
Factors such as new product launches and benefits offered by generic drugs are boosting the market. In addition, the growing pharmaceutical industry in developing countries is likely to have a positive impact on the growth of the market in the coming years. The ongoing research and development activities are aiding the market growth. Moreover, the leading players in the market are innovating and launching enhanced products, which is expected to have a positive effect on the industry growth over the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report gives a detailed analysis of the following key players in the global generic oncology drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Molecule Type||
|Breakup by Route of Administration||
|Breakup by Distribution Channel||
|Breakup by Region||
|Report Price and Purchase Option||Explore our purchase options that are best suited to your resources and industry needs.|
|Delivery Format||Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Generic Oncology Drugs Market Overview
6.1 Global Generic Oncology Drugs Market Historical Value (2017-2023)
6.2 Global Generic Oncology Drugs Market Forecast Value (2024-2032)
7 Global Generic Oncology Drugs Market Landscape
7.1 Global Generic Oncology Drugs Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Generic Oncology Drugs Product Landscape
7.2.1 Analysis by Molecule
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Distribution Channel
8 Generic Oncology Drug Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Generic Oncology Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Generic Oncology Drugs Market Segmentation
11.1 Global Generic Oncology Drugs Market by Molecule Type
11.1.1 Market Overview
11.1.2 Large Molecule
11.1.3 Small Molecule
11.2 Global Generic Oncology Drugs Market by Route of Administration
11.2.1 Market Overview
11.3 Global Generic Oncology Drugs Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Online Pharmacy
11.3.4 Retail Pharmacy
11.4 Global Generic Oncology Drugs Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Generic Oncology Drugs Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Generic Oncology Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Generic Oncology Drugs Market
14.1 Market Share by Country
15 Latin America Generic Oncology Drugs Market
15.1 Market Share by Country
16 Middle East and Africa Generic Oncology Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
23 Supplier Landscape
23.1 Novartis AG
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 Pfizer Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 GlaxoSmithKline plc
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Teva Pharmaceutical Industries Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 Merk & Company, Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Aurobindo Pharma.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 Hikma Pharmaceuticals PLC
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Mylan N.V.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 NATCO Pharma Limited
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 CELGENE CORPORATION
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
24 Global Generic Oncology Drugs Market - Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
In 2023, the global market of generic oncology drugs attained a value of USD 25.3 billion.
The market is anticipated to grow at a CAGR of 6.2% during the forecast period of 2024-2032 to reach a value of USD 43.7 billion by 2032.
The major drivers of the industry include rising disposable incomes, increasing population, rising cancer incidences, rising demand for these drugs to assist patients undergoing chemotherapy, alleviating after-effects, including pain, availability of advanced technology and enhanced healthcare infrastructure.
The increased government expenditure in the healthcare industry is expected to be a key trend guiding the growth of the industry.
North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market, with North America accounting for the largest market share.
The leading players in the market are Mylan N.V., Hikma Pharmaceuticals PLC, Stason Pharmaceuticals, and Mayne Pharma, among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.